Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits

Bone(2020)10.1016/j.bone.2020.115625Source: DataRank Database

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits is a research paper published in Bone (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.82)OA: greenTopics (41)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

R. Clay Bunn,Sasidhar Uppuganti ORCID,Philip D. Ray,Iuliana Popescu ORCID,Evangelia Kalaitzoglou ORCID

Live enrichment

PubMed:32890778 PMC:PMC7852344 OpenAlex:https://openalex.org/W3081713711

Department of Veterans Affairs

Grant: 1I01BX004297

National Institutes of Health

Grant: R21AR070620

National Institutes of Health

Grant: R56DK084045

BLRD VA

Grant: I01 BX004297

National Institutes of Health

Grant: 2R56DK084045-05A1

The insulin/IGF axis in diabetic osteopathy

National Institutes of Health

Grant: 1R21AR070620-01

Effects of Sodium-dependent Glucose Co-transporter 2 Inhibition on Bone.

National Institutes of Health

Grant: 5I01BX004297-04

Diabetes-Related Changes Affecting Bone Quality

University of Kentucky

FWCI

0.82

Citation Percentile

0.7%

Citation Trend

2020

2021

2022

2023

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7852344

publisherhttps://api.elsevier.com/content/article/PII:S8756328220304051?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S8756328220304051?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bone.2020.115625

Fields of Study

Metabolism, Diabetes, and CancerDiabetes Treatment and ManagementCardiovascular Function and Risk Factors0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

CanagliflozinSodium-Glucose Transporter 2 InhibitorsAnimalsBlood GlucoseDiabetes Mellitus, Type 2Pharmaceutical PreparationsMaleMice

Keywords

Internal medicineMedicineEndocrinologyCanagliflozinCortical boneBone mineralGlycemicDiabetes mellitusOsteoporosisBone densityQuantitative computed tomographyType 2 diabetesFemurSurgeryAnatomyFractureAnimal ModelsBone MicroarchitectureBone ΜctPhosphate WastingBlood GlucoseMaleMiceDiabetes Mellitus, Type 2Pharmaceutical PreparationsAnimalsSodium-Glucose Transporter 2 Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits

FAIR Checklist

Authors (8)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)